Overview

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Status:
Recruiting
Trial end date:
2024-09-24
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, double-blind, placebo-controlled study to demonstrate the effect of oral ozanimod as maintenance therapy in subjects with moderately to severely active Crohn's Disease.
Phase:
Phase 3
Details
Lead Sponsor:
Celgene
Treatments:
Ozanimod